Vident Investment Advisory LLC lessened its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 13.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,606 shares of the medical instruments supplier’s stock after selling 391 shares during the quarter. Vident Investment Advisory LLC’s holdings in Becton Dickinson and were worth $624,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Bartlett & Co. LLC grew its holdings in Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 435 shares during the last quarter. BDO Wealth Advisors LLC boosted its stake in shares of Becton Dickinson and by 361.6% during the first quarter. BDO Wealth Advisors LLC now owns 577 shares of the medical instruments supplier’s stock valued at $125,000 after acquiring an additional 452 shares during the last quarter. Kaizen Advisory LLC boosted its stake in shares of Becton Dickinson and by 155.9% during the second quarter. Kaizen Advisory LLC now owns 609 shares of the medical instruments supplier’s stock valued at $146,000 after acquiring an additional 371 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Becton Dickinson and during the second quarter valued at $163,000. Finally, Clarus Wealth Advisors acquired a new stake in shares of Becton Dickinson and during the second quarter valued at $188,000. Institutional investors and hedge funds own 92.51% of the company’s stock.
BDX has been the topic of a number of analyst reports. KeyCorp reaffirmed a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a research note on Friday, August 3rd. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Citigroup raised their price target on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $280.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 4th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $253.79.
NYSE BDX traded up $4.13 during mid-day trading on Friday, reaching $242.62. 1,127,659 shares of the company’s stock traded hands, compared to its average volume of 1,159,369. Becton Dickinson and Co has a 1-year low of $197.44 and a 1-year high of $265.87. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. The firm has a market cap of $69.83 billion, a PE ratio of 25.59, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11.
Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm had revenue of $4.28 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter last year, the firm earned $2.46 EPS. Becton Dickinson and’s quarterly revenue was up 41.0% on a year-over-year basis. On average, analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 28th. Stockholders of record on Friday, September 7th were given a $0.75 dividend. The ex-dividend date was Thursday, September 6th. This represents a $3.00 annualized dividend and a dividend yield of 1.24%. Becton Dickinson and’s payout ratio is 31.65%.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.